Pernix Therapeutics Hldgs buy klostergang
Zusammenfassung
Diese Einschätzung wurde am 07.12.15 mit einem Endkurs von 25,98 € beendet. Mit einer Rendite von -14,29 % entwickelte sich die Einschätzung BUY nicht nach Plan. klostergang hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Pernix Therapeutics Hldgs | - | - | - | - |
| iShares Core DAX® | 1,08 % | -0,85 % | 12,46 % | 58,47 % |
| iShares Nasdaq 100 | -1,67 % | -3,31 % | 1,50 % | 84,47 % |
| iShares Nikkei 225® | 3,86 % | 6,31 % | 22,27 % | 56,19 % |
| iShares S&P 500 | 0,11 % | -1,34 % | 1,10 % | 58,32 % |
Kommentare von klostergang zu dieser Einschätzung
In der Diskussion Pernix Therapeutics Hldgs diskutieren
PTX is too cheap given its growth prospects and earnings trajectory!
Pernix Therapeutics (NASDAQ:PTX) is just one of a myriad small pharmaceuticals that have seen their stocks under pressure due to the fallout and collapse of Valeant Pharmaceuticals. After a big decline in its shares, the company reported blowout quarterly results this week.
At just $3.25 a share, the stock is too cheap given its growth prospects and earnings trajectory.
Earning Highlights: Pernix posted earnings of eight cents a share, seven cents a share above the consensus.Revenues climbed almost 55% year-over-year to just under $49 million for the quarter, just under $2 million above the consensus.Adjusted EBITDA increased to $8.7 million, compared to just under $7 million during the prior year period.
The company has three core products, Silenor, Treximit and Zohydro, that all have good growth prospects and decent patent expirations.